SHR-1701

Clinical trials for SHR-1701 explained in plain language.

Never miss a new study

Get alerted when new SHR-1701 trials appear

Sign up with your email to follow new studies for SHR-1701, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1

New immunotherapy combo aims to improve lung cancer outcomes

Disease control Not yet recruiting

This phase II trial tests an immunotherapy drug called SHR-1701 combined with chemotherapy and radiation for people with unresectable stage III non-small cell lung cancer. The study will enroll 84 participants and compare giving SHR-1701 before or after standard chemoradiation. T…

Matched conditions: SHR-1701

Phase: PHASE2 • Sponsor: Fudan University • Aim: Disease control

Last updated Jun 27, 2026 13:00 UTC

SHR-1701

Get alerted when new SHR-1701 trials appear

New immunotherapy combo aims to improve lung cancer outcomes